Slide 1: Strong Foundation. Accelerating Growth.
STRONG FOUNDATION. ACCELERATING GROWTH.
Slide 2: Safe Harbor
Safe Harbor Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "p
Slide 3: Solara Is A Young BUT An Experienced Company
Solara Is A Young BUT An Experienced Company… Demonstrated operational excellence over 3 decades • Demerged the select API business of Strides Shasun • Demerged Human API business from SeQuent to to integrate with human API business of SeQuent operate as Pure Play animal healthcare company • Expansi
Slide 4: Solara's Business Model Is Well Suited To Benefit From Emerging Trends
Solara’s Business Model Is Well Suited To Benefit From Emerging Trends… While the opportunity is growing, it needs a focused play USFDA’s increasing Supply chain IP conflicts and Increasing Pollution and oversight on APIs diversification competing interests Environmental Concerns • FDA’s increased o
Slide 5: Business Model Underpinned By Scale Of Operations and Depth In Capabilities
Solara’s Business Model Is Underpinned By Its Scale Of Operations and Depth In Capabilities… API business model with large scale infrastructure, wide products and established customer relationships Capabilities Research Complex chemistry capabilities including Pipeline of 25+ handling of catalytic h
Slide 6: Strong And Anchored Values Drive Actions Towards Stakeholders
Strong And Anchored Values Drive Actions Towards Positive Engagements With All Its Stakeholders… INTEGRITY Our business stands on the pillar of integrity, honesty and RESPECT fairness. Everything we do here We at Solara respect our stands the test of public Employees, Customers and scrutiny Partners
Slide 7: Solara At A Glance
Solara Brings Solid Infrastructure In Both Manufacturing And R&D… Experience Manufacturing Sites 30 + 6 Years of Legacy Solara At a People Research and Glance Development +2300 Centers Employees 2 Successful USFDA Audits 24 7
Slide 8: Solara Leadership Team Has More Than A Century Of Collective Experience
Solara Leadership Team Has More Than A Century Of Collective And Relevant Experience Bharath R. Sesha (Bharath) Hariharan S. (Hari) MD & CEO Executive Director Bharath has over two decades of experience across Hariharan is a Cost Accountant with rich diverse industries. His expertise spans across th
Slide 9: Solara Leadership Team Has More Than A Century Of Collective Experience
Solara Leadership Team Has More Than A Century Of Collective And Relevant Experience Roy Joseph Sundara Moorthy V. (Sundar) CHRO CQO Roy has over 30 years of multifaceted Sundar has rich and diversified experience of 23 years experience in industrial Relations, in the Quality Management, Regulatory
Slide 10: Solara Board Of Directors Guide The Organization
Solara Board Of Directors Guide The Organization Based On Their Diverse And Rich Experience Deepak Vaidya Nirmal Bhogilal R. Ramakrishnan Independent Director Non-Exec. Director & Chairman Independent Director He is a practicing Chartered Fellow member of the ICA in Chairman of the Batliboi Accounta
Slide 11: Solara Well Poised For Accelerated Growth
2° SOLARA Solara Well Poised For Accelerated Growth
Slide 12: Solara Has Robust Manufacturing Capabilities
Solara Has Robust Manufacturing Capabilities… Core focus • Provide reliability to customers via mirror facilities for key products Ambernath • Deploy systems that are highly automated for ensuring consistent operations EU GMP • Focus on technology and production processes that represent a clear adva
Slide 13: Facilities Offer Wide Ranging Capabilities: Pondicherry and Cuddalore
Facilities Offer Wide Ranging Capabilities Suited For A Diverse Product Portfolio… Pondicherry Facility • The buildings for the manufacturing of Intermediates and isolation of final drug substance are separate. • Packing sections are controlled and meets ISO Class - 8 requirements. • Reactors are in
Slide 14: Facilities Offer Wide Ranging Capabilities: Mangalore and Ambernath
Facilities Offer Wide Ranging Capabilities Suited For A Diverse Product Portfolio… Multipurpose Mangalore Facility ▪ Multi purpose cGMP API and intermediate facility inspected by DCD, USFDA, WHO, EDQM, MFDS, TGA, AEMPS, ISO-14001 ▪ 6 Full fledged cleanrooms meeting ISO class-8 slandered can hand six
Slide 15: Solara announces commencement of phase 1 of new greenfield facility at Vizag
Solara announces commencement of phase 1 of its new greenfield facility at Vizag, India 15
Slide 16: Phase 1 goes on stream for Ibuprofen; Phase 2 multipurpose API
Phase 1 goes on stream for Ibuprofen • 3,600 TPA new capacity goes on stream from Q2’21 • Ibuprofen capacity for Solara augments to 8,400 TPA with significant capacity commitments and long-term contracts • DCS controlled automation with compliance of 21CFR part 11. • Peak capacity expected to reach
Slide 17: In House R&D Enables Continuous Launch Of New Products
In House R&D Brings Significant Speed And Capabilities To Enable Continuous Launch Of New Products Two India based R&D Centre for best in class product development Technical Expertise Strong technical leadership to develop high-quality pharma products that create strategic value for our partners and
Slide 18: Strong Track Record Of Regulatory Approvals
A Strong Track Record Of Regulatory Approvals Provides Peace Of Mind To Our Customers… Latest Inspections at Regulatory Agency Puducherry Cuddalore Mangalore Ambernath United States Feb-2020 Mar-2020 Feb-2020 Jan-2019 Europe Nov-2014 Jan-2017 Sept-2017 Oct-2017 Geneva - Oct-2016 Feb-2018 - India Jun
Slide 19: Strong Track Record Of Regulatory Approvals
A Strong Track Record Of Regulatory Approvals Provides Peace Of Mind To Our Customers… Latest Inspections at Regulatory Agency Puducherry Cuddalore Mangalore Ambernath MFDS, South Korea Feb 2017 Nov 2012 Jul 2018 --- Mexico Sep 2015 Sep 2015 --- --- Slovenia Feb 2015 --- --- --- Denmark Oct 2008 Oct
Slide 20: A Growing Product Portfolio Enables Wider Opportunities
A Growing Product Portfolio Enables Wider Opportunities And Stronger Customer Relationships Rich basket of niche high value products for the global markets DMF FILING RUN RATE GEOGRAPHY WISE FILINGS 9 8 6 6 4 82 11 FY16 FY17 FY18 FY19 FY20 • 80+ Commercial APIs predominantly in Anthelmintic, Anti-ma
Slide 21: Financials
Financials Tete Pharma Scenes
Slide 22: FY20 - A Solid year of operational excellence
FY20 - A Solid year of operational excellence… Revenues ₹ 13,493m 4% YoY EBITDA ₹ 2,793m 21% YoY PAT ₹ 1,145m 71% YoY 22
Slide 23: FY20 – A strong year for operating efficiencies and profitability
FY20 – A strong year for operating efficiencies and profitability YoY Performance Highlights Business and Operations Update Optimal product mix, favorable outcomes of cost improvement programs Particulars FY20 FY19 Change and revenues from new products led to a 390-basis point improvement in the O
Slide 24: Highest ever revenues and profitability in H1'21
Strategic play delivers the highest ever revenues and profitability for Solara in H1’21 Revenues Reported EBITDA EBITDA% PAT EPS ₹ 7,567m ₹ 1,869m 24.7% ₹ 990m ₹34.96 H1’21 H1’21 H1’21 H1’21 H1’21 H1’20 H1’20 H1’20 H1’20 H1’20 6,906 1,368 19.8% 554 21.50 YoY% YoY YoY% YoY% YoY% 37% 490bps 63% 10% 79
Slide 25: H1 performance demonstrates a healthy base for future growth
H1 performance demonstrates a healthy base for the future growth and outlook Half yearly Performance Business and Operations Update Particulars H1 '21 H1 '20 Change Regulated markets revenues at ₹ 5,774 million, up by 12% YoY and contributed 76% of H1’21 revenues Revenue 7,567 6,906 10% Gross marg
Slide 26: Significantly strong balance sheet for efficient growth
Significantly strong balance sheet for an efficient growth going forward Statement of Assets and Liabilities Key Highlights Source of Funds *ROCE% ** ROE% # Fixed Assets Turnover Particulars Rs Mn Mar’20 Jun’20 Sep’20 18.9 16.8 % 15.9 16.3 Shareholders' funds 10,859 11,294 14,748 % % 1.7 1.7 % Less:
Slide 27: Strong momentum continues in growth, PAT and EPS
Strong momentum continues in growth, PAT and EPS EBITDA (₹ Million) Profit After Tax (₹ Million) Basic EPS (₹/share) 1200 0.5 19.2 1006 0.45 567 16.0 15.7 1000 863 0.4 820 0.35 413 423 800 705 663 11.2 25% 0.3 10.3 23% 605 24% 600 20% 20% 0.25 289 20% 265 0.2 6.8 400 178 0.15 0.1 200 0.05 0 0 Q1'20
Slide 28: Guidance: Reaffirming revenue growth, increasing EBITDA guidance
Guidance: Reaffirming revenue growth outlook and increasing EBITDA guidance from ~25-30% earlier to ~40-42% YoY growth Revenues EBITDA EBITDA Margins FY19 Performance ₹ 13,991m ₹ 2,316m 17% FY20 Performance ₹ 13,493m ₹ 2,793m 21% FY21E ~25-30% YoY ~25-30% YoY High teens Previous Guidance FY21E Revis
Slide 29: Solara — The Road Ahead
Fess Pharma Sciences WA \\ \ Solara — The Road \ \Y\ Ahead...
Slide 30: The Growth Strategy Is Along Five Levers
The Growth Strategy Is Along Five Levers, Complimenting And Amplifying Each Other … Strong foundation… ...Leading To Accelerating Growth 01 CUSTOMER CENTRICITY 05 NEW PRODUCTS/MARKETS 04 Solara has strong customer In a short span of 2 years Solara has relationships lasting many years. We established
Slide 31: Key focus areas for the year FY21
Key focus areas for the year FY 21 GROWTH & SUSTAINING NEW GROWTH LEVERS THE EXISTING BUSINESS NEW PRODUCTS & CRAMS • Transitioning to a strategic relationship with customers • Expand share of New Product launches in the past years to based on high advocacy and supply assurance driven by new markets
Slide 32: Well Poised To Significantly Accelerate Growth and Value Creation
Based On A Strong Foundation, Solara Is Well Poised To Significantly Accelerate Growth and Value Creation… Deep and diverse capabilities across the spectrum of manufacturing and R&D Strong market presence across the world with sales in 75+ countries Growing product portfolio with 40+ active products
Slide 33: Thank You
THANK YOU REGISTERED OFFICE 201, Devavrata, Sector 17, Vashi, Navi Mumbai - 400 703. Tel.: +91 22 2789 2924 Fax No. +91 22 2789 2942 Email: investors@solara.co.in Website: www.solara.co.in CIN: U24230MH2017PLC291636 CORPORATE OFFICE 3rd & 4th Floor, Batra Centre, No.28, Sardar Patel Road, Guindy, Ch